149,908 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 149,908 shares of the company’s stock, valued at approximately $17,190,000.

Other hedge funds also recently bought and sold shares of the company. Merck & Co. Inc. purchased a new position in shares of Kymera Therapeutics in the second quarter worth approximately $88,544,161,000. Deutsche Bank AG purchased a new stake in shares of Kymera Therapeutics in the 2nd quarter valued at approximately $12,161,000. Vanguard Group Inc. lifted its position in shares of Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after acquiring an additional 845,922 shares in the last quarter. Eagle Health Investments LP acquired a new position in Kymera Therapeutics in the 2nd quarter worth approximately $19,052,000. Finally, BlackRock Inc. acquired a new position in Kymera Therapeutics in the 2nd quarter worth approximately $635,067,000.

Insider Activity at Kymera Therapeutics

In related news, Director Bvf Partners L. P/Il sold 1,578,800 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $106.50, for a total value of $168,142,200.00. Following the transaction, the director owned 240,123 shares in the company, valued at approximately $25,573,099.50. This represents a 86.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Bruce Booth sold 31,283 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $109.48, for a total transaction of $3,424,862.84. Following the transaction, the director directly owned 461,794 shares in the company, valued at approximately $50,557,207.12. The trade was a 6.34% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 3,587,629 shares of company stock worth $386,183,782. 15.98% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on KYMR. Royal Bank Of Canada downgraded shares of Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and boosted their target price for the company from $106.00 to $115.00 in a research note on Monday, July 13th. Truist Financial raised their target price on Kymera Therapeutics from $116.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Mizuho increased their price objective on Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a research note on Thursday, July 16th. Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, BTIG Research reiterated a “buy” rating and issued a $134.00 target price on shares of Kymera Therapeutics in a report on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Kymera Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $125.65.

Kymera Therapeutics Stock Up 4.6%

Kymera Therapeutics stock opened at $126.64 on Wednesday. The company’s fifty day simple moving average is $110.92 and its 200-day simple moving average is $92.80. Kymera Therapeutics, Inc. has a 12 month low of $39.84 and a 12 month high of $130.05. The stock has a market cap of $10.53 billion, a P/E ratio of -39.09 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The business had revenue of $65.00 million during the quarter, compared to analyst estimates of $32.78 million. During the same period last year, the company earned ($0.95) earnings per share. Kymera Therapeutics’s quarterly revenue was up 465.2% compared to the same quarter last year. On average, equities research analysts expect that Kymera Therapeutics, Inc. will post -3.75 earnings per share for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.